Method Profile
Patient-derived head and neck cancer organoids assess CD8-positive T-cell activation and tumor killing after the three-part treatment.
Preclinical comparison of a repurposed drug with radiation and immune checkpoint blockade in a human-derived tumor model.
Patient-derived HNSCC organoids with the T-cell response system reported in the original study.
Radiotherapy, atovaquone and PD-1/PD-L1 blockade are examined together; separate syngeneic mouse models assess tumor growth and immune populations.
Tumor model
Patient-derived three-dimensional head and neck squamous cell carcinoma organoids.
Interventions
Atovaquone, radiation and PD-1 or PD-L1 checkpoint blockade.
Relate the measured T-cell activation to organoid killing; retain the mouse tumor-growth evidence as a separate model layer.
Patient-derived organoid evaluation of the triple combination.
Patient-derived head and neck squamous cell carcinoma organoid models.
The treatment conditions and references reported by the investigators.
The combination increased CD8-positive T-cell activation and tumor killing.
Radiotherapy, atovaquone and PD-1/PD-L1 blockade increased CD8-positive T-cell activation and tumor killing in patient-derived head and neck cancer organoids. Separate mouse experiments showed substantial differences among tumor models.
